HeartFlow has raised $936M through multiple rounds including $65M Series E (2019), $216M Series F (2023), and $98.4M Series F (2025) with investors such as Bain Capital Life Sciences, Fidelity, Janus Henderson, USVP, and Capricorn. Founded in 2007, HeartFlow leverages CT imaging and high-performance computing to create patient-specific 3D coronary blood-flow models, improving diagnostic accuracy and reducing unnecessary invasive procedures. Funding has supported clinical validation, regulatory filing, and hospital adoption programs. HeartFlow’s technology enables cardiologists to non-invasively assess coronary disease and guide treatment decisions globally.